Drug name - Opsumit

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7094781 ACTELION Sulfamides and their use as endothelin receptor antagonists
Dec, 2025

(3 years from now)

CN100432070C ACTELION Novel Sulfonamide Compounds And Their Use As Endothelin Receptor Antagonists
Dec, 2020

(1 year, 9 months ago)

CN1524079A ACTELION Novel Sulfonamide Compounds And Their Use As Endothelin Receptor Antagonists
Dec, 2020

(1 year, 9 months ago)

EP1345920B1 ACTELION Novel Sulfamides And Their Use As Endothelin Receptor Antagonists
Dec, 2026

(4 years from now)

EP1345920A1 ACTELION Novel Sulfamides And Their Use As Endothelin Receptor Antagonists
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10946015 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide Sep, 2026

(3 years from now)

US9265762 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide May, 2027

(4 years from now)

US8367685 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide Oct, 2028

(6 years from now)

US8268847 ACTELION Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor Apr, 2029

(6 years from now)

Drugs and Companies using MACITENTAN ingredient

Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition; Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition; Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.